Skip to content
PubMed This is a summary of 22 peer-reviewed journal articles Updated
Endocrinology

Standard of Care and Treatment Priority

At a Glance

Panhypophysitis treatment usually begins with hormone replacement, especially hydrocortisone before levothyroxine when cortisol is low to prevent adrenal crisis. Desmopressin needs individualized fluid and sodium monitoring, while high-dose steroids or surgery are reserved for selected complications.

Treating panhypophysitis is a multi-step process that focuses on two goals: replacing the hormones your body can no longer produce and, if necessary, reducing the physical swelling of the pituitary gland [1][2]. Because the pituitary controls so many systems, the order of operations in your treatment is a matter of safety [3].

(Disclaimer: Symptom checklists are not diagnostic, and patients should never start, stop, double, or taper hormone medications without a clinician’s direct plan).

The Gold Standard: Hormone Replacement

Hormone replacement is the most critical part of your care. Most patients with panhypophysitis will need to take medications that “fill the gap” left by the underperforming pituitary [4].

  • Adrenal Support (Glucocorticoids): You will likely be prescribed hydrocortisone or prednisone to replace cortisol. This is the most important medication in your regimen [5]. (Note: Central adrenal insufficiency usually does not require fludrocortisone because aldosterone is generally preserved).
  • Thyroid Support (Levothyroxine): If your free T4 levels are low, you will take a synthetic thyroid hormone [6].
  • Water Balance (Desmopressin): If you have confirmed central diabetes insipidus, you will use desmopressin (usually as a pill or nasal spray) to stop excessive thirst and urination [2].
  • Other Hormones: Depending on your needs, you may also receive sex hormone replacement (estrogen or testosterone) or growth hormone [1][7]. Sex-hormone replacement, fertility treatment, and growth hormone are separate decisions with their own contraindications and monitoring, particularly for people receiving cancer treatment. Prolactin is not routinely replaced.

Why “Steroids First” Matters

There is a critical safety rule in endocrinology: Adrenal insufficiency must be treated before thyroid deficiency [1].

If you start taking thyroid medication (levothyroxine) while your cortisol levels are still low, it can speed up your body’s metabolism so quickly that it triggers a life-threatening adrenal crisis [3]. Your doctor will ensure your cortisol is stable before adding thyroid hormone to your plan [8].

(Note: Starting glucocorticoid replacement can unmask or worsen polyuria in someone with both adrenal insufficiency and diabetes insipidus).

Managing Desmopressin Safely

Desmopressin is not just a simple pill to stop thirst; it carries significant safety hazards. Over-replacement or excessive fluid intake can cause water intoxication (dilutional hyponatremia), which may present with headache, nausea, confusion, seizures, or reduced consciousness. Too little can cause severe dehydration.

  • Do not change your desmopressin dose or deliberately restrict or force fluids without your treating team’s instructions.
  • Dosing often includes an individualized sodium-monitoring plan and a planned period for breakthrough urination.

High-Dose Steroids vs. Replacement

It is easy to confuse “replacement steroids” with “high-dose steroids.” They serve very different purposes:

  1. Replacement Doses: Low, physiologic doses (like 15–25mg of hydrocortisone daily) that simply mimic what a healthy body makes. These are often needed for life [4][5]. Do not stop them abruptly.
  2. High-Dose (Supraphysiologic) Steroids: Clinician-directed very high doses used as a tool to aggressively shrink inflammation [9].

High-dose steroids are generally reserved for when the swollen pituitary is pressing on the optic nerves or causing severe, intractable headaches [10]. While they can shrink the gland and improve vision, they do not always “wake up” the pituitary; hormone loss often remains even after the swelling goes down [11][12]. These doses vary by protocol and carry major risks like infection and hyperglycemia.

The Role of Surgery

Surgery is not the standard treatment for panhypophysitis [13]. Because the condition is an inflammatory process—not a solid tumor—it often responds better to medical treatment than to a scalpel [14]. However, rapidly deteriorating vision requires immediate neuro-ophthalmology or neurosurgical assessment, and urgent surgical decompression or tissue biopsy may be required to rule out cancer [15][9].

Managing ICI-Induced Hypophysitis

If your condition was caused by immune checkpoint inhibitors (ICIs) for cancer treatment, your management is slightly different:

  • Do not schedule, take, or permanently stop another dose on your own. Immune checkpoint therapy is generally held during an acute or clinically significant immune-related adverse event [16][17].
  • Continuing Cancer Treatment: Resumption of immunotherapy depends on the severity of the hypophysitis, visual or neurologic findings, other toxicities, and the oncology team’s protocol. Oncology and endocrinology will make that decision together [18][19]. Physiologic hormone replacement is often compatible with later ICI resumption [20].

Your Safety Net: Sick Day Rules

Because your body cannot produce its own “stress” cortisol, you must learn Sick Day Rules [21]. You should always carry an emergency injection kit and wear medical-alert identification to ensure emergency responders know you require hydrocortisone [22][5].

Common questions in this guide

Why does hydrocortisone need to come before levothyroxine in panhypophysitis?
When panhypophysitis causes low cortisol and low thyroid hormone, adrenal insufficiency should be treated first. Starting levothyroxine before cortisol is replaced can speed up the body’s metabolism and trigger a life-threatening adrenal crisis. Follow the order and doses prescribed by your clinician.
What hormone replacement medicines might I need for panhypophysitis?
Treatment may include hydrocortisone or prednisone for cortisol deficiency, levothyroxine for low thyroid hormone, and desmopressin when central diabetes insipidus causes excessive thirst and urination. Some people also need estrogen, testosterone, or growth hormone, depending on their deficiencies and other health conditions. These treatments require individualized monitoring, and prolactin is not routinely replaced.
How can I use desmopressin safely?
Too much desmopressin or drinking excessive fluid can dilute the sodium in your blood and cause headache, nausea, confusion, seizures, or reduced consciousness. Too little can lead to severe dehydration. Do not change the dose or force or restrict fluids on your own; your treating team should set the fluid plan, sodium checks, and any planned breakthrough urination.
What is the difference between steroid replacement and high-dose steroids for panhypophysitis?
Replacement hydrocortisone or prednisone supplies the cortisol your body is not making and may be needed long term, so it should not be stopped suddenly. High-dose steroids are clinician-directed treatment intended to reduce pituitary inflammation, usually when swelling threatens vision or causes severe persistent headaches. They can carry risks such as infection and high blood sugar, and reducing swelling may not restore lost hormone production.
Is surgery usually needed for panhypophysitis?
No. Panhypophysitis is usually managed medically because it is an inflammatory condition rather than a solid tumor. Rapidly worsening vision requires urgent neuro-ophthalmology or neurosurgical assessment, and decompression or a biopsy may be considered to relieve pressure or rule out cancer.
What should I do about cancer immunotherapy if I develop ICI-induced hypophysitis?
Immune checkpoint inhibitor treatment is generally held during an acute or clinically significant hypophysitis event, but you should not pause, restart, or permanently stop it without your oncology team. Oncology and endocrinology weigh the severity, vision or neurologic findings, and other toxicities before deciding whether treatment can resume. Physiologic hormone replacement is often compatible with later resumption.
What are sick-day rules for panhypophysitis with adrenal insufficiency?
Sick-day rules explain when your clinician wants you to adjust hydrocortisone during illness or injury and when to use emergency hydrocortisone. Keep an emergency injection kit available, learn how to use it if vomiting prevents you from taking pills, and wear medical-alert identification. Your clinician should provide the exact individualized instructions.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Am I currently on a safe replacement dose of hydrocortisone, and do I have a 'Sick Day Plan' for when I am ill or injured?
  2. 2.Since I have both low cortisol and low thyroid, can you confirm that we are starting my hydrocortisone before my levothyroxine?
  3. 3.Is the goal of my current steroid dose to shrink the inflammation or just to replace what my body isn't making?
  4. 4.If I am using desmopressin, how much fluid should I be drinking daily, and how often will we check my sodium levels?
  5. 5.For ICI-induced cases: How will oncology and endocrinology coordinate regarding the pausing or resumption of my cancer treatment?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (22)
  1. 1

    Hypopituitarism.

    Higham CE, Johannsson G, Shalet SM

    Lancet (London, England) 2016; (388(10058)):2403-2415 doi:10.1016/S0140-6736(16)30053-8.

    PMID: 27041067
  2. 2

    Primary and Ipilimumab-induced Hypophysitis: A Single-center Case Series.

    Atkins P, Ur E

    Endocrine research 2020; (45(4)):246-253 doi:10.1080/07435800.2020.1817064.

    PMID: 32892666
  3. 3

    Endocrinology Update: Hypopituitarism.

    Heidelbaugh JJ

    FP essentials 2016; (451()):25-30.

    PMID: 27936532
  4. 4

    Effects of glucocorticoid replacement therapy in patients with pituitary disease: A new perspective for personalized replacement therapy.

    Chiloiro S, Vicari A, Mongelli G, et al.

    Reviews in endocrine & metabolic disorders 2024; (25(5)):855-873 doi:10.1007/s11154-024-09898-6.

    PMID: 39168952
  5. 5

    Investigation of the Hypothalamo-pituitary-adrenal (HPA) axis: a contemporary synthesis.

    Karaca Z, Grossman A, Kelestimur F

    Reviews in endocrine & metabolic disorders 2021; (22(2)):179-204 doi:10.1007/s11154-020-09611-3.

    PMID: 33770352
  6. 6

    Masked type 1 diabetes mellitus (T1DM) unveiled by glucocorticoid replacement: a case of simultaneous development of T1DM and hypophysitis in an elderly woman.

    Aikawa E, Horie I, Naganobu K, et al.

    Endocrine journal 2020; (67(11)):1163-1168 doi:10.1507/endocrj.EJ20-0213.

    PMID: 32669510
  7. 7

    Approach to the Patient: A Case With an Unusual Cause of Hypopituitarism.

    Das L, Dutta P

    The Journal of clinical endocrinology and metabolism 2023; (108(6)):1488-1504 doi:10.1210/clinem/dgac747.

    PMID: 36573291
  8. 8

    Adrenal insufficiency.

    Husebye ES, Pearce SH, Krone NP, Kämpe O

    Lancet (London, England) 2021; (397(10274)):613-629 doi:10.1016/S0140-6736(21)00136-7.

    PMID: 33484633
  9. 9

    New causes of hypophysitis.

    Yuen KCJ, Popovic V, Trainer PJ

    Best practice & research. Clinical endocrinology & metabolism 2019; (33(2)):101276 doi:10.1016/j.beem.2019.04.010.

    PMID: 31078416
  10. 10

    A Novel Etiology of Hypophysitis: Immune Checkpoint Inhibitors.

    Fernandes S, Varlamov EV, McCartney S, Fleseriu M

    Endocrinology and metabolism clinics of North America 2020; (49(3)):387-399 doi:10.1016/j.ecl.2020.05.002.

    PMID: 32741478
  11. 11

    Early Pulse Glucocorticoid Therapy and Improved Hormonal Outcomes in Primary Hypophysitis.

    Krishnappa B, Shah R, Sarathi V, et al.

    Neuroendocrinology 2022; (112(2)):186-195 doi:10.1159/000516006.

    PMID: 33744880
  12. 12

    MRI Findings of Immune Checkpoint Inhibitor-Induced Hypophysitis: Possible Association with Fibrosis.

    Kurokawa R, Ota Y, Gonoi W, et al.

    AJNR. American journal of neuroradiology 2020; (41(9)):1683-1689 doi:10.3174/ajnr.A6692.

    PMID: 32763900
  13. 13

    Evaluation and follow-up of patients diagnosed with hypophysitis: a cohort study.

    Hacioglu A, Karaca Z, Uysal S, et al.

    European journal of endocrinology 2024; (191(3)):312-322 doi:10.1093/ejendo/lvae101.

    PMID: 39186535
  14. 14

    The Diagnostic Challenge of Hypophysitis vs. Non-Functioning Pituitary Macroadenomas: An Updated Review and Comparative Analysis of Distinguishing Criteria.

    Ach T, Bouzaouech I, Gasmi A, et al.

    Diagnostics (Basel, Switzerland) 2026; (16(2)) doi:10.3390/diagnostics16020328.

    PMID: 41594303
  15. 15

    Characteristics of inflammatory and infectious diseases of the pituitary gland in patients undergoing transsphenoidal surgery.

    Naser PV, Papadopoulou P, Teuber J, et al.

    Pituitary 2023; (26(4)):451-460 doi:10.1007/s11102-023-01333-4.

    PMID: 37389775
  16. 16

    Hypophysitis from immune checkpoint inhibitors: challenges in diagnosis and management.

    Kotwal A

    Current opinion in endocrinology, diabetes, and obesity 2021; (28(4)):427-434 doi:10.1097/MED.0000000000000652.

    PMID: 34183541
  17. 17

    Diagnostic criteria and proposed management of immune-related endocrinopathies following immune checkpoint inhibitor therapy for cancer.

    Percik R, Criseno S, Adam S, et al.

    Endocrine connections 2023; (12(5)).

    PMID: 36884258
  18. 18

    Immune checkpoint inhibitor induced hypophysitis: a specific disease of corticotrophs?

    Patel N, Hirwa K, Gardner G, et al.

    Endocrine connections 2024; (13(11)).

    PMID: 39348229
  19. 19

    Retrospective analysis of clinical characteristics and treatment of patients with immune checkpoint inhibitors-induced adrenal insufficiency.

    Huang X, Zhang L, Zhang C, et al.

    Frontiers in oncology 2025; (15()):1614223 doi:10.3389/fonc.2025.1614223.

    PMID: 40919154
  20. 20

    Clinical characteristics and management of PD-1/PD-L1 inhibitor-induced secondary adrenal insufficiency.

    Li N, Liang T, Xie H, Niu Y

    Endocrine connections 2026; (15(4)).

    PMID: 41973678
  21. 21

    Emergency management of adrenal insufficiency in children: advocating for treatment options in outpatient and field settings.

    Miller BS, Spencer SP, Geffner ME, et al.

    Journal of investigative medicine : the official publication of the American Federation for Clinical Research 2020; (68(1)):16-25 doi:10.1136/jim-2019-000999.

    PMID: 30819831
  22. 22

    Surgical treatment of a 72-year-old patient with headache, hyponatremia and oculomotor nerve palsy: a case report and literature review.

    Huang H, Jiang S, Yang C, et al.

    Gland surgery 2021; (10(1)):364-370 doi:10.21037/gs-20-517.

    PMID: 33633993

This page is for informational purposes only and does not constitute medical advice. Do not change hormone replacement, desmopressin, or steroid doses without an individualized plan from your treating clinicians.

Get notified when new evidence is published on Panhypophysitis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.